Publication |
2021
Abstract
A retrospective SPEAR study involving more than 10,000 patients attempted to indirectly compare the efficacy of abiraterone and enzalutamide in a first-line metastatic castration-resistant prostate cancer (mCRPC) in chemonautical patients. Most of them (64%) were treated with abiraterone, while 36% of patients were treated with enzalutamide.
Although the so-called propensity score methodology was used, it was not a prospective randomized study. Better results were seen in the enzalutamide group.
The results of the SPEAR study raised a number of issues that should be further analyzed.